Nabriva Therapeutics plc NBRV
1.42 +1.42
Day range unavailable
52-week range unavailable
Revenue & Expenses
Latest period ending Dec 31, 2022 · select a line to chart its full history
Income statement
| Fiscal year | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 | FY 2019 Dec 31, 2019 | FY 2018 Dec 31, 2018 |
|---|---|---|---|---|---|
| 36.94M | 28.89M | 5.03M | 9.48M | 9.66M | |
| 8.35M | 15.75M | 4.26M | 9.41M | 9.66M | |
| -55.49M | -48.53M | -66.13M | -79.49M | -114.38M | |
| -57.19M | -49.45M | -69.48M | -82.76M | -114.78M | |
| -2.13 | -2.85 | -13.52 | -27.88 | -56.50 |
Balance sheet
| Fiscal year | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 | FY 2019 Dec 31, 2019 | FY 2018 Dec 31, 2018 |
|---|---|---|---|---|---|
| 12.54M | 47.83M | 41.59M | 86.41M | 102.00M | |
| 31.77M | 80.91M | 58.44M | 94.11M | 110.42M | |
| 28.47M | 27.56M | 25.30M | 52.84M | 41.79M | |
| 5.22M | 8.03M | 7.73M | 34.50M | 23.72M | |
| 3.29M | 53.35M | 33.13M | 41.27M | 68.63M |
Cash flow
| Fiscal year | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 | FY 2019 Dec 31, 2019 | FY 2018 Dec 31, 2018 |
|---|---|---|---|---|---|
| -36.71M | -59.56M | -71.33M | -71.89M | -72.72M | |
| -263.00K | -81.00K | -274.00K | 331.00K | -4.60M | |
| 1.85M | 66.37M | 26.92M | 56.08M | 92.92M | |
| -211.00K | -25.00K | -113.00K | -61.00K | -229.00K | |
| -35.30M | 6.24M | -44.82M | -15.59M | 15.23M |